Medicine and Dentistry
Patient
100%
Hepatocellular Carcinoma
86%
Liver
35%
Chronic Hepatitis B
31%
Inpatient
28%
Therapeutic Procedure
26%
Liver Cirrhosis
19%
Hepatitis B Virus
17%
Liver Fibrosis
17%
Transcatheter Arterial Chemoembolization
15%
Fibrosis
15%
Measurement
14%
Antiviral Therapy
14%
Overall Survival
14%
Development
13%
Age
12%
Sorafenib
11%
Hazard Ratio
11%
Neoplasm
10%
Fatty Liver
10%
Combination Therapy
10%
Surgery
9%
Nonalcoholic Fatty Liver
9%
Entecavir
9%
Predictor
9%
Recurrent Disease
8%
Survival
8%
Chemotherapy
7%
Platelet
7%
Transient Elastography
7%
Hepatitis B
7%
Follow up
6%
Antivirus Agent
6%
Diagnosis
6%
Alanine Aminotransferase
6%
Male
6%
Hepatic Arterial Infusion
5%
Hepatitis B(e) Antigen
5%
Alpha-Fetoprotein
5%
Multivariate Analysis
5%
Odds Ratio
5%
Association
5%
Liver Cancer
5%
Hepatitis B Antigen
5%
Tenofovir Disoproxil
5%
Man
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
31%
Chronic Hepatitis B
17%
Entecavir
12%
Hepatitis B Virus
10%
Lamivudine
9%
Fibrosis
8%
Liver Cirrhosis
8%
Antivirus Agent
6%
Tenofovir Disoproxil
6%
Hepatitis B(e) Antigen
6%
Recurrent Disease
5%
Sorafenib
5%
Liver Cell Carcinoma
5%
Virus DNA
5%
Fatty Liver
5%
Nursing and Health Professions
Patient
18%
Inpatient
10%
Chronic Hepatitis B
7%
Liver Cirrhosis
6%
Liver Stiffness
5%